Stockscreener 앱 받기
10.86
0.56%
0.06
시간 외 거래:
10.87
0.010
+0.09%
Climb Bio Inc 주식(CLYM)의 최신 뉴스
Climb Bio's Upcoming Data Updates on CLYM116, Budoprutug to Be 'More Incremental,' RBC Says - marketscreener.com
H.C. Wainwright reiterates Climb Bio stock rating ahead of data By Investing.com - Investing.com Canada
Climb Bio, Inc. (CLYM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Alpha Cognition Inc. Common Stock (ACOG) Stock Price, News, Quote & History - Yahoo! Finance Canada
Climb Bio to present Phase 2 data on kidney disease therapies - Investing.com Nigeria
Climb Bio to Present Preliminary Phase 2 Budoprutug Data in Primary Membranous Nephropathy at ASN Kidney Week 2026 - Quiver Quantitative
Climb Bio to present Phase 2 data on kidney disease therapies - Investing.com UK
Climb Bio (NasdaqGM:CLYM) Stock Forecast & Analyst Predictions - simplywall.st
Preliminary data from a kidney disease drug study were selected for an October talk. - Stock Titan
Form 4 Climb Bio Inc For: 1 October - Investing.com India
Form 4 Climb Bio Inc For: 1 October By Investing.com - Investing.com Canada
Form 4 Climb Bio Inc For: 1 October By Investing.com - Investing.com Nigeria
Options for 70,000 shares were exercised at $1.29–$7.89 in Climb Bio (CLYM). - Stock Titan
Form 4 Climb Bio Inc For: 1 October By Investing.com - Investing.com Australia
Nuvectis Pharma (Nasdaq:NVCT)Stock Analysis - simplywall.st
About $19 million in liabilities are extinguished after a $450,000 payment to settle litigation. - stocktitan.net
Director Stephen Thomas Sells 100,000 Shares of Climb Bio Inc (CLYM) - GuruFocus
Climb Bio (CLYM) director sells 100K shares in preset plan - Stock Titan
Climb Bio (NASDAQ: CLYM) director files to sell insider stake - Stock Titan
Climb Bio presents initial Phase 1 data for CLYM116 - Traders Union
Climb Bio at Wells Fargo conference: two antibody bets draw focus - Investing.com Nigeria
Climb Bio at Wells Fargo conference: two antibody bets draw focus - Investing.com Canada
Climb Bio at Wells Fargo conference: two antibody bets draw focus - Investing.com UK
H.C. Wainwright raises Climb Bio stock price target on drug data By Investing.com - Investing.com Australia
H.C. Wainwright raises Climb Bio stock price target on drug data - Investing.com Australia
Oppenheimer Adjusts Price Target on Climb Bio to $25 From $18, Maintains Outperform Rating - Moomoo
H.C. Wainwright raises Climb Bio stock price target on drug data - Investing.com Nigeria
Oppenheimer Adjusts Price Target on Climb Bio to $25 From $18, Maintains Outperform Rating - marketscreener.com
H.C. Wainwright raises Climb Bio stock price target on drug data - investing.com
H.C. Wainwright raises Climb Bio stock price target on drug data - Investing.com Canada
Oppenheimer raises Climb Bio stock price target on IgAN data By Investing.com - Investing.com Canada
Oppenheimer raises Climb Bio stock price target on IgAN data By Investing.com - Investing.com South Africa
Oppenheimer raises Climb Bio stock price target on IgAN data By Investing.com - Investing.com India
H.C. Wainwright raises Climb Bio stock price target on drug data - Investing.com UK
Oppenheimer raises Climb Bio stock price target on IgAN data - Investing.com
Oppenheimer raises Climb Bio stock price target on IgAN data - Investing.com
H.C. Wainwright Maintains Climb Bio(CLYM.US) With Buy Rating, Raises Target Price to $30 - Moomoo
Oppenheimer raises Climb Bio stock price target on IgAN data By Investing.com - Investing.com Nigeria
Truist Financial Maintains Climb Bio(CLYM.US) With Buy Rating - Moomoo
A Quick Look at Today's Ratings for Climb Bio(CLYM.US), With a Forecast Between $25 to $40 - Moomoo
Baird raises Climb Bio stock price target to $25 on trial data - Investing.com Canada
Baird raises Climb Bio stock price target to $25 on trial data - Investing.com Australia
Baird raises Climb Bio stock price target to $25 on trial data - Investing.com India
BTIG raises Climb Bio stock price target to $32 on phase 1 data - Investing.com Australia
Baird raises Climb Bio stock price target to $25 on trial data By Investing.com - Investing.com South Africa
BTIG raises Climb Bio stock price target to $32 on phase 1 data By Investing.com - Investing.com South Africa
Baird raises Climb Bio stock price target to $25 on trial data - Investing.com Nigeria
BTIG raises Climb Bio stock price target to $32 on phase 1 data - Investing.com Canada
BTIG raises Climb Bio stock price target to $32 on phase 1 data - Investing.com
BTIG raises Climb Bio stock price target to $32 on phase 1 data - Investing.com India
4.29%
0.85%
자본화:
|
볼륨(24시간):